Scarica l'app Stockscreener
92.08
0.52%
0.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$91.66
Aprire:
$90.75
Volume 24 ore:
180.07K
Relative Volume:
0.22
Capitalizzazione di mercato:
$5.55B
Reddito:
$521.31M
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-192.60
EPS:
-0.4781
Flusso di cassa netto:
$54.87M
1 W Prestazione:
+2.63%
1M Prestazione:
-12.66%
6M Prestazione:
+23.88%
1 anno Prestazione:
+95.50%
Intervallo 1D:
$90.00
$94.16
Intervallo di 1 settimana:
$89.74
$96.65
Portata 52W:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
91.97 | 5.53B | 521.31M | -23.36M | 54.87M | -0.4781 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.57 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.00 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Why Mirum Pharmaceuticals Stock Is Sinking Today - TipRanks
Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 40,985 Shares - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 16,515 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 4,732 Shares - MarketBeat
Mirum Pharma’s chief medical officer Quan sells $670k in stock - Investing.com Canada
Mirum Pharmaceuticals Executives Sell Shares - TradingView
Mirum (NASDAQ: MIRM) CFO exercises performance RSUs, sells shares to cover tax withholding - Stock Titan
Mirum (MIRM) CMO exercises performance RSUs, sells 7,287 shares for tax - Stock Titan
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs - Stock Titan
Mirum (NASDAQ: MIRM) SVP exercises PRSUs, sells 4,732 shares for taxes - Stock Titan
Mirum (MIRM) CEO sells shares to cover tax from RSU vesting - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) files to sell 7,287 vested RSU shares - Stock Titan
Joanne Quan to Sell 7,287 Mirum Shares (NASDAQ: MIRM) via Morgan Stanley - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider files to sell 16,515 shares - Stock Titan
Mirum Pharmaceuticals (MIRM) files Form 144: proposed resale of vested RSUs - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider sells vested RSUs totaling multiple transactions - Stock Titan
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli - The Globe and Mail
Mirum completes enrollment & screening in liver disease studies - MSN
Citizens reiterates Mirum Pharmaceuticals stock rating on trial progress - Investing.com
Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum completes enrollment in cholestatic pruritus trial By Investing.com - Investing.com India
Trading Recap: Is Mirum Pharmaceuticals Inc a turnaround story2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Mirum Pharmaceuticals releases latest announcement details - Traders Union
Saira Ramasastry to sell 2,000 shares via option exercise (NASDAQ: MIRM) - Stock Titan
Mirum completes enrollment in cholestatic pruritus trial - Investing.com
Rare liver disease trial of Mirum itch drug finishes signup - Stock Titan
Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Eventide Asset Management LLC Sells 114,922 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Reduced by Boone Capital Management LLC - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Aug Patterns: Can Mirum Pharmaceuticals Inc benefit from deglobalization2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)? - simplywall.st
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals (MIRM) president and COO exercises options, lifts stake - Stock Titan
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans By Investing.com - Investing.com Canada
Mirum Pharmaceuticals at Citizens Life Sciences: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (MIRM) and Scalable Risk - Stock Traders Daily
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) earnings expected to grow: What to know ahead of Q4 release - MSN
Mirum’s Brelovitug Phase 3 Milestones Reframe Rare Disease Growth Story - simplywall.st
Mirum Finishes Participant Enrollment and Screening for Liver Disease Research - Bitget
Mirum Completes Enrollment & Screening in Liver Disease Studies - Barchart.com
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
1.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):